US2021069221A1PendingUtilityA1

Materials and methods for suppressing and/or treating bacterial infections and related symptoms

Assignee: UNIV INDIANA RES & TECH CORPPriority: Aug 3, 2017Filed: Aug 20, 2020Published: Mar 11, 2021
Est. expiryAug 3, 2037(~11 yrs left)· nominal 20-yr term from priority
A61K 31/506A61P 31/04A61K 31/7008
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistence to the treatment, prevention, and diagnosis of diseases/symptoms induced by infectious bacteria. Embodiments include methods of treating a bacterial infection, comprising the steps of: providing to a patient diagnosed with staphylococcal infection at least one therapeutically effective dose of a compound having an anti-virulence effect.

Claims

exact text as granted — not AI-modified
1 . A method of treating a bacterial infection, comprising the steps of:
 providing to a patient at least one therapeutically effective dose of a compound according to the Formula 1:   
       
         
           
           
               
               
           
         
       
     
     
         2 . The method of  claim 1 , wherein the compound is a pharmaceutically acceptable salt of Formula 1, or a metabolite thereof. 
     
     
         3 . The method of  claims 1 - 2 , wherein the patent is diagnosed with a staphylococcal infection or a similar condition. 
     
     
         4 . The method of any one of  claims 1 - 3 , wherein the bacterial infection comprises a staphylococcal infection that causes at least one symptom comprising skin infection, pneumonia, bone infection, toxic shock syndrome, blood poisoning, endocarditis, and a combination thereof. 
     
     
         5 . The method of any one of  claims 1 - 4 , further including the step of:
 identifying a patent at risk for a staphylococcal infection or a similar condition.   
     
     
         6 . The method of any one of  claims 1 - 5 , wherein the therapeutically effective dose of the compound according to Formula 1, is on the order of between about 15 mg to about 1700 mg and the dose of the compound is administered to the patient at least once per day. 
     
     
         17 .- 22 . (canceled)

Join the waitlist — get patent alerts

Track US2021069221A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.